Liver Neoplasms

Oncology
0
Pipeline Programs
3
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 4 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

HistoSonics
HistoSonicsMI - Ann Arbor
3 programs
HistoSonics Edison SystemN/A1 trial
HistoSonics SystemN/A1 trial
HistoSonics SystemN/A1 trial
Active Trials
NCT06486454Recruiting5,000Est. Nov 2031
NCT04573881Active Not Recruiting24Est. Aug 2027
NCT04572633Active Not Recruiting47Est. Sep 2027
E
EisaiChina - Liaoning
1 program
Non-interventionalN/A1 trial
Active Trials
NCT05225207Completed658Est. Jan 2022
Bayer
BayerLEVERKUSEN, Germany
1 program
RegorafenibN/ASmall Molecule1 trial
Active Trials
NCT03289273Completed1,010Est. Jun 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
HistoSonicsHistoSonics Edison System
HistoSonicsHistoSonics System
HistoSonicsHistoSonics System
EisaiNon-interventional
BayerRegorafenib

Clinical Trials (5)

Total enrollment: 6,739 patients across 5 trials

NCT06486454HistoSonicsHistoSonics Edison System

Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)

Start: Oct 2024Est. completion: Nov 20315,000 patients
N/ARecruiting
NCT04573881HistoSonicsHistoSonics System

The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (#HOPE4LIVER EU/UK)

Start: Jun 2021Est. completion: Aug 202724 patients
N/AActive Not Recruiting
NCT04572633HistoSonicsHistoSonics System

The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy

Start: Jan 2021Est. completion: Sep 202747 patients
N/AActive Not Recruiting
NCT05225207EisaiNon-interventional

A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) Participants

Start: May 2019Est. completion: Jan 2022658 patients
N/ACompleted
NCT03289273BayerRegorafenib

Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)

Start: Sep 2017Est. completion: Jun 20221,010 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
16m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
16m ago

Office Administrator

SystImmune
16m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
26m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
30m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
30m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 6,739 patients
3 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)